PhD-student
Julie Bjerrelund
Department of Endocrinology, Odense University Hospital
Projekt styring | ||
Projekt status | Open | |
Data indsamlingsdatoer | ||
Start | 01.01.2025 | |
Slut | - | |
SHORT-GLOBE is a randomized crossover study that compares the biological effects of native GLP-1 (7-36) or saline on bone formation in 12 healthy individuals.
Bone is constantly remodeled by a coupled process of resorption by osteoclasts and formation of by osteoblasts. Glucagon-like peptide 1 (GLP-1), secreted postprandially, has emerged as a potential regulator of bone remodeling. Recently our group showed that short-term GLP-1 exposure (two hours) in vivo led to an 80% reduction in the bone resorption marker Collagen I, cross-linked C-terminal telopeptide (CTX) in bone marrow serum from healthy young males. In contrast, preliminary data from our group have shown that three-days exposure to GLP-1 in-vitro increases the activity of both osteoclasts and osteoblasts. The in vitro findings have not been corroborated by physiological studies. As such, the understanding of the relevance of GLP-1 to human bone physiology currently only covers acute effects. Furthermore, a clinical trial conducted on non-diabetic individuals undergoing long-term treatment with the GLP-1 receptor agonist (GLP-1RA), semaglutide, demonstrated an increase in the bone resorption marker CTX. The discrepancy between immediate effects observed in vivo and longer-term effects seen in the clinical trial underscores the need to clarify the effect of extended GLP-1 exposure in vivo. The ambition of this study is to outline the effect of native GLP-1 in the skeleton. Specifically, this study will demonstrate the impact of four days exposure to native GLP-1 on bone turnover in healthy individuals.
Healthy participants between 18 and 40 years of age.
Blood samples, bone marrow samples and bone biopsies.